DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

BI and DRG Analyst Briefing: An Analysis of the Increasingly Competitive Neurostimulation Market

This live session took place on September 18, 2018 in partnership with Bloomberg Intelligence

The world-wide neurostimulation market is catching the eye of many within the medtech, pharmaceutical and investing industries. This is because of the accelerated growth in the U.S. and European markets and the over 100 million potential patients with chronic pain, Parkinson’s disease, epilepsy and many more indications that can be treated with neurostimulators. Bloomberg Intelligence and Decision Resources Group co-hosted a webinar discussion on the current and future breakdown of the overall neurostimulation market and its potential to impact the aforementioned industries.

Our analysts discussed:

  • Who are neurostimulation patients and what is the disease population for each indication
  • The market size and growth rates of the spinal cord, deep brain, sacral nerve and vagus nerve stimulation markets
  • The impact of new devices, such as Medtronic Intellis, Boston Scientific WaveWriter, Nevro HF10 and Abbott Burst DR devices, on the current landscape
  • Previous investments in the space and future investment opportunities such as treating Arthritis, Alzheimer’s and investigating less invasive ways to treat chronic pain
  • The use of spinal cord stimulation as an alternative to opioids and the impact on the market of future regulatory changes
  • Emerging products in the pipeline

Please complete the form below view the webinar recording